Kerr Douglas 4

What Happened

• Kerr Douglas, Chief Medical Officer of Dyne Therapeutics (DYN), disposed of 904 shares on 2026-03-05 at $14.90 per share for proceeds of $13,470. The sale was an automatic disposition to satisfy tax withholding tied to vesting restricted stock units, not a discretionary open-market trade.

Key Details

• Transaction date and price: 2026-03-05, 904 shares sold at $14.90 each.
• Proceeds: $13,470.
• Transaction type/codes: Sale (S); tax-withholding disposition (F) per the filing.
• Shares owned after transaction: the filing notes holdings that include 153,625 unvested RSUs (per footnote).
• Footnotes: F1 — automatic sale to satisfy tax withholding under the RSU agreement; treated as a binding contract consistent with a Rule 10b5-1 affirmative defense and not a discretionary trade. F2 — includes 153,625 unvested RSUs.
• Filing timeliness: Report filed 2026-03-06 for a 2026-03-05 transaction — filed within the standard 2-business-day window.

Context

• This sale was a routine, automatic tax-withholding transaction tied to RSU vesting and does not necessarily signal insider sentiment about the company. For retail investors, purchases typically carry more interpretive weight than automatic tax-related sales.